Safety of potassium-binding agents in HFrEF: a meta-analysis of randomized trials
Hyperkalemia is a common challenge in the management of heart failure with reduced ejection fraction (HFrEF) and often limits optimization of guideline-directed medical therapy (GDMT). In this setting, potassium-binding agents such as patiromer and sodium zirconium cyclosilicate (SZC) have gained increasing atten...